AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 52 min read$TEM

Fukushima Ryan sold $1.1M of TEM (indirect holdings)

Fukushima Ryan (CEO, Data) sold 23,818 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $46.19 ($43.25–$46.94, $1.10M total) across 5 trades on 2026-08-03 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Fukushima Ryan
Published Aug 5, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$TEM
Neutral
medium confidence
Mentioned
$TEM
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMNeutralLow
01

Why it matters

The newest disclosed fact is the $1.10M open-market sale executed across five trades on 2026-08-03 under a pre-arranged 10b5-1 plan, filed on 2026-08-05.

02

Market read

Traders may monitor insider activity for sentiment, but this specific disclosure is routine 10b5-1 selling with no accompanying operational or financial update.

03

What to watch

The filing notes indirect holdings and post-transaction share count, but provides no rationale for the sale; without follow-on buys or guidance changes, trading impact is likely limited.

Relevance 5/10Novelty 3/10Timing: SEC Form 4 filed 2026-08-05, covering sales executed 2026-08-03.

Background

The article is an SEC Form 4 insider transaction report for Tempus AI, Inc. (TEM) by CEO, Data Fukushima Ryan.

Company-level read

Ticker impact

$TEMNeutralMedium confidence
Context

Tempus AI CEO Fukushima Ryan sold $1.10M of TEM shares via a 10b5-1 plan, with weighted-average prices $46.19 across five trades.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal beyond routine 10b5-1 selling.

Evidence & confidence

The filing is a Form 4 open-market sale by an officer with an explicitly pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Sector

Minimal, as the disclosure is company-specific and does not indicate sector-wide regulatory or demand changes.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because the sale is under a 10b5-1 plan, it may reflect liquidity management rather than bearish expectations, so any price reaction may be overstated.

Key entities

  • issuer
    Tempus AI, Inc.

    Subject of the Form 4 insider sale disclosure (TEM).

  • insider
    Fukushima Ryan

    CEO, Data who executed the indirect open-market sale under a 10b5-1 plan.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

TEM insider trading history →

Related articles

OCT 26
$TEMMed

What Happens To Tempus AI Stock If Its Cash Burn Continues?

Tempus AI (TEM) expects positive free cash flow by year-end but had a $273M cash burn over the past year. With $816M in cash, the company's reserves could last about three years at current burn rates. Revenue grew 20% and 36% in diagnostics and data businesses, respectively. Management raised 2026 revenue guidance to $1.595B-$1.605B and issued $460M in convertible notes. The company plans to acquire Personalis, potentially using debt to fund the deal.

finance.yahoo.com2 min
OCT 26
$BMYMed

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

Pathos AI has partnered with Bristol Myers Squibb (BMY) and Tempus (TEM) to advance AI-driven drug development for Alzheimer’s and other neurological conditions. Tempus will create a dataset from hundreds of thousands of patients, which Pathos will license for $55 million over five years. BMY leads Pathos's Series E financing and gains access to Pathos's AI platform, Pathos Foundry, for its R&D portfolio, with exclusive rights in neuroscience for three years.

biospace.com3 min
OCT 24
$BMYMed

Tempus Sets $55 Million Ceiling for Pathos Neurology Data Contract

Tempus AI signed a five-year neurology data deal with Pathos AI, potentially worth $55 million. Tempus will deliver up to 500,000 records, with Pathos paying $100 per record. Bristol Myers Squibb gains nonexclusive Foundry access and three-year exclusive rights for neuroscience development. Tempus also has a $137.5 million oncology deal with BMS, totaling $192.5 million if both deals reach full value.

econotimes.com2 min
OCT 23
$TEMMed

Tempus AI Gains 6% as Bristol Myers Squibb Licenses Oncology Data

Tempus AI shares rose 6% after Bristol Myers Squibb agreed to a multi-year deal to license its oncology data through 2031. Tempus's data and AI platform will support BMS's drug discovery and development. Data licensing is Tempus's most profitable segment, with 36% revenue growth in Q2. The financial terms of the deal were not disclosed.

finance.yahoo.com2 min